Connor, Clark & Lunn Investment Management (CC&L)
RVMD icon

Connor, Clark & Lunn Investment Management (CC&L)’s Revolution Medicines RVMD Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-91,720
Closed -$8.92M – 1770
2026
Q1 		$8.92M Buy
+91,720
New +$9.26M 0.02% 504
2025
Q4 		– Sell
-191,327
Closed -$8.93M – 1754
2025
Q3 		$8.93M Buy
191,327
+158,632
+485% +$6.21M 0.03% 438
2025
Q2 		$1.2M Sell
32,695
-147,067
-82% -$5.65M ﹤0.01% 999
2025
Q1 		$6.36M Sell
179,762
-28,639
-14% -$1.16M 0.03% 435
2024
Q4 		$9.12M Buy
208,401
+181,500
+675% +$9.16M 0.04% 341
2024
Q3 		$1.22M Buy
+26,901
New +$1.17M 0.01% 820
2024
Q2 		– Sell
-44,938
Closed -$1.45M – 1652
2024
Q1 		$1.45M Buy
+44,938
New +$1.33M 0.01% 771
2022
Q3 		– Sell
-12,033
Closed -$235K – 1232
2022
Q2 		$235K Buy
+12,033
New +$234K ﹤0.01% 907

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RVMD Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 91,720 shares — an estimated $8.92M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RVMD in Q2 2022 and held it in 8 quarters. The position peaked at $9.12M in Q4 2024. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 91,720 Revolution Medicines shares in Q2 2026, an estimated $8.92M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Revolution Medicines in Q2 2022 and held it in 8 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Revolution Medicines position peaked at $9.12M in Q4 2024.
  • 688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.